首页|布地奈德、特布他林、异丙托溴铵雾化对哮喘患儿影响

布地奈德、特布他林、异丙托溴铵雾化对哮喘患儿影响

扫码查看
目的 研究布地奈德、特布他林、异丙托溴铵雾化吸入对哮喘患儿影响.方法 选择彭州市人民医院2018年1月至2020年12月收治的哮喘患儿120例,按随机数表法分为观察组和对照组各60例,其中对照组使用布地奈德+特布他林雾化吸入治疗,观察组在对照组基础上加用异丙托溴铵雾化吸入治疗,均连续治疗 7 d.观察两组患儿治疗前后肺功能指标为用力肺活量FVC)、第 1s用力呼气容积(FEV1)、最大呼气流量(PEF)、血清免疫球蛋白M(IgM)、血清免疫球蛋白G(iIgG)、血清免疫球蛋白A(IgA)、痰液及血清中嗜酸性粒细胞(EOS)和嗜酸性细胞阳离子蛋白(ECP)含量,统计治疗后气喘消失、咳嗽消失、哮鸣音消失及住院时间,并于治疗后实施为期6月(截止2021年6月)随访调查,采用儿童哮喘控制测试量表(C-ACT)记录疾病控制情况.结果 观察组治疗后FVC、FEV1、PEF均高于对照组,差异有统计学意义(P<0.05),观察组治疗后IgM、IgG、IgA含量均高于对照组,差异有统计学意义(P<0.05),观察组治疗后痰诱导液及血清中EOS、ECP含量均低于对照组,差异有统计学意义(P<0.05).观察组治疗后气喘消失、咳嗽消失、哮鸣音消失、住院时间均低于对照组,差异有统计学意义(P<0.05),观察组随访3月哮喘控制情况优于对照组,差异有统计学意义(P<0.05),两组随访6月哮喘控制情况相当,差异无统计学意义(P>0.05).结论 哮喘患儿使用布地奈德联合特布他林及异丙托溴铵雾化吸入治疗能有效改善患儿肺功能、血清免疫球蛋白含量及气道炎症反应,进而缩短临床症状缓解时间,并在一定程度上改善疾病控制情况.
Effects of nebulization of budesonide,terbutaline and ipratropium bromide on children with asthma
Objective To study the effects of budesonide combined with terbutaline and ipratro-pium bromide nebulized inhalation on immune function and lung function in children with asthma.Methods 120 children with asthma admitted to Pediatrics of Pengzhou People's Hospital from January 2018 to December 2020 were selected.They were divide into two groups:an observation group and a control group with 60 cases each based on the random number table.The control group received budesonide+terbutaline nebulized inhala-tion treatment,while the observation group was treated with ipratropium bromide nebulized inhalation on the ba-sis of the control group,and the treatment was continuous for 7 days.Lung function indexes of both groups were observed before and after treatment:forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),maximum expiratory flow(PEF),serum immunoglobulin M(IgM),serum immunoglobulin G(iIgG),serum immunoglobulin A(IgA),eosinophils(EOS)and eosinophil cationic protein(ECP)levels in sputum and serum,statistics of asthma disappeared,cough disappeared,wheezing disappeared and hospitaliza-tion post-treatment were recorded.A 6-month follow-up survey(as of June 2021)was carried out,and the child-hood asthma control test scale(C-ACT)was used to monitor disease control.Results After treatment,the FVC,FEV1 and PEF of the observation group were all higher than those of the control group,the difference was statistically significant(P<0.05),and the levels of IgM,IgG and IgA in the observation group were higher than those of the control group after treatment,the difference was statistically significant(P<0.05).Sputum in-duction in the observation group after treatment showed lower contents of EOS and ECP in both the liquid and serum compared to the control group,the difference was statistically significant(P<0.05).After treatment,the observation group experienced disappearance of asthma,cough,wheezing,as well as a shorter hospital stay compared to the control group,and the difference was statistically significant(P<0.05).The observation group also demonstrated better asthma control during the 3-month follow-up period compared to the control group,and the difference was statistically significant(P<0.05).During the 6-month follow-up period,the asthma control situation was similar between the two groups,with not statistically significant difference(P>0.05).Conclusion The use of budesonide combined with terbutaline and ipratropium bromide,in nebulized inhala-tion therapy for children with asthma can effectively enhance the children's lung function,serum immunoglobu-lin levels and reduce airway inflammation.This,in turn,can shorten the time needed for clinical symptom relief and improve disease control to some extent.

AsthmaNebulized inhalationBudesonideTerbutalineIpratropium bromide

胡楠、王燕、黄莲

展开 >

彭州市人民医院儿科,四川,成都 611930

哮喘 雾化吸入 布地奈德 特布他林 异丙托溴铵

湖北省青年人才项目

WJ2019H162

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(6)